Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Dec 2024 value amounting to -$1.85.

  • Mirum Pharmaceuticals' EPS (Weighted Average and Diluted) rose 116.67% to $0.05 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.86, marking a year-over-year increase of 58.65%. This contributed to the annual value of -$1.85 for FY2024, which is 53.75% up from last year.
  • As of FY2024, Mirum Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$1.85, which was up 53.75% from -$4 recorded in FY2023.
  • Mirum Pharmaceuticals' EPS (Weighted Average and Diluted)'s 5-year high stood at -$1.85 during FY2024, with a 5-year trough of -$4.02 in FY2022.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$3.29, with a median of -$4 in 2023.
  • Per our database at Business Quant, Mirum Pharmaceuticals' EPS (Weighted Average and Diluted) tumbled by 45.13% in 2022 and then spiked by 53.75% in 2024.
  • Over the past 4 years, Mirum Pharmaceuticals' EPS (Weighted Average and Diluted) (Yearly) stood at -$2.77 in 2021, then crashed by 45.13% to -$4.02 in 2022, then grew by 0.50% to -$4 in 2023, then spiked by 53.75% to -$1.85 in 2024.